AWHL · XBRL financial data

Aspira Women's Health financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AWHL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	4,651	6,812	8,184	9,154	4,000	343
Revenue from contracts with customers	—	—	—	9,154	9,182	9,216
Cost of goods and services sold	3,415	3,750	3,861	3,892	3,703	3,301
Gross profit	1,236	3,062	4,323	5,262	5,479	5,915
Research and development	2,104	5,314	5,917	4,035	3,266	2,878
General and administrative	8,270	13,257	14,629	12,267	10,345	7,964
Total operating expenses	19,217	35,657	35,461	24,114	21,757	13,828
Operating income (loss)	(17,981)	(32,595)	(31,138)	(18,852)	(16,278)	(7,913)
Other income (expense)	66	981	(468)	485	1,871	1,809
Income tax expense (benefit)	0	—	—	—	—	—
Net income (loss)	(17,905)	(31,662)	(29,885)	(16,690)	(13,094)	(12,780)
Earnings per share, basic USD per share	(0.18)	(0.28)	(3.85)	(1.81)	(0.93)	(0.37)
Earnings per share, diluted USD per share	(0.18)	(0.28)	(3.85)	(1.81)	(0.93)	(0.37)
Weighted average shares, basic thousands of shares	100,723	111,211	7,769	9,233	14,135	34,103
Weighted average shares, diluted thousands of shares	100,723	111,211	7,769	9,233	14,135	34,103

† Share count changed about 1/10 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (AWHL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	16,631	37,180	13,306	2,597	1,769	1,755
Accounts receivable	865	1,027	1,245	1,459	990	1,207
Inventory	30	174	316	227	326	256
Prepaid and other current assets	1,077	1,624	1,442	997	1,098	845
Total current assets	18,603	40,005	16,309	5,280	4,183	4,063
Property and equipment, net	583	464	368	165	69	47
Right-of-use asset	406	346	282	528	1,194	980
Total assets	19,605	41,079	17,373	6,262	5,491	5,456
Accounts payable	1,149	1,501	881	1,261	2,173	1,237
Accrued liabilities	3,618	5,299	3,402	2,863	2,445	1,297
Current portion of long-term debt	999	201	403	166	229	236
Total current liabilities	6,400	7,840	5,527	5,119	5,468	3,465
Long-term debt	3,077	2,718	2,315	1,430	1,278	1,041
Lease liability, non-current	409	349	272	427	1,248	1,008
Total liabilities	9,886	10,907	10,394	8,627	8,054	12,388
Accumulated deficit	(440,066)	(471,728)	(501,613)	(518,303)	(531,397)	(544,177)
Total stockholders' equity	9,719	30,172	6,979	(2,365)	(2,563)	(6,932)
Total liabilities and equity	19,605	41,079	17,373	6,262	5,491	5,456
Common shares outstanding (cover page) thousands of shares	111,717	112,139	124,943	12,344	29,764	43,500

† Share count changed about 1/10 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (AWHL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(17,905)	(31,662)	(29,885)	(16,690)	(13,094)	(12,780)
Stock-based compensation	1,548	3,539	2,414	1,724	1,494	531
Depreciation and amortization	265	302	264	199	—	—
Net cash from operating activities	(14,734)	(27,395)	(31,068)	(15,894)	(12,113)	(7,029)
Purchases of property and equipment	490	184	232	24	37	16
Net cash from investing activities	(490)	(184)	(232)	(24)	(37)	(401)
Proceeds from issuing common stock	—	48,235	9,000	202	—	—
Net cash from financing activities	20,152	48,378	7,427	5,216	11,064	7,416
Net change in cash	4,928	20,799	(23,873)	(10,702)	(1,086)	(14)

† Share count changed about 1/10 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Viskase Holdings	7,747	95,279	454*	14.3M	—	Q3 FY26 10-QSep 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Xenetic Biosciences	6,472	661	(875)*	2.3M	7.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.